Where is the live CopyMark page for USPTO serial 75493478?

The live record is at https://getcopymark.com/trademark/75493478. Use https://getcopymark.com/trademark/{serialNumber} for any 8-digit USPTO serial.

Who owns IMMUNOGENEX?

According to the public USPTO record for serial number 75493478, the listed owner(s) include: IMMUNOGENEX, INC., IMMUNOGENEX, INC..

What is USPTO serial number 75493478?

Serial number 75493478 is the USPTO application identifier for the mark IMMUNOGENEX. It is used to track examination, publication, and registration of this trademark.

Which trademark classes cover IMMUNOGENEX?

The public record lists International Classes: 040, 042. Each class corresponds to categories of goods or services identified in the application or registration.

Trademark: IMMUNOGENEX Serial# 75493478 | status 608; last event PR.W | Trademark Info & Attorney Guidance

Q: What is the current status of IMMUNOGENEX?

IMMUNOGENEX (75493478) currently shows USPTO status code 608 on the public record. This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with IMMUNOGENEX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner

Monitor this mark, or talk with CopyMark about this registration.

Trademark Monitoring

(312) 319-4460

Not the owner?

File a new U.S. trademark application, or speak with our attorneys.

Start a new application

(312) 319-4460

Owner

IMMUNOGENEX, INC.
San Diego, CA
Other trademarks owned by IMMUNOGENEX, INC.
IMMUNOGENEX, INC.
San Diego, CA
Other trademarks owned by IMMUNOGENEX, INC.

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

KEVIN A CAHILL

KEVIN A CAHILL SULLIVAN WERTZ MCDADE & WALLACE945 4TH AVESAN DIEGO, CA 92101UNITED STATES

Goods and services

Class	Description	Status	First use
040	Manufacture of general product lines in the field of pharmaceuticals and biotechnology to the order and specification of others	ACTIVE	—
042	Research and development services for others, medical laboratory testing services for others, and consulting services for others, all of the foregoing in the pharmaceutical, biotechnology or medical device industries	ACTIVE	—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Date	Code	Event	What it means
Aug 31, 2001	PR.W	PETITION TO REVIVE WITHDRAWN	—
Jun 11, 2001	PR.W	PETITION TO REVIVE WITHDRAWN	—
Nov 27, 2000	PETR	PETITION TO REVIVE-RECEIVED	—
Nov 27, 2000	PETR	PETITION TO REVIVE-RECEIVED	—
Apr 11, 2000	ABN6	ABANDONMENT - NO USE STATEMENT FILED	The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Aug 17, 1999	NOAM	NOA MAILED - SOU REQUIRED FROM APPLICANT	A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 25, 1999	PUBO	PUBLISHED FOR OPPOSITION	Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 23, 1999	NPUB	NOTICE OF PUBLICATION	—
Feb 26, 1999	DOCK	ASSIGNED TO EXAMINER	—
Feb 17, 1999	CNSA	APPROVED FOR PUB - PRINCIPAL REGISTER	—
Feb 4, 1999	CNEA	EXAMINER'S AMENDMENT MAILED	—
Jan 7, 1999	DOCK	ASSIGNED TO EXAMINER	—

IMMUNOGENEX